Macular telangiectasia – Basic Information

Go back

Macular telangiectasia is a rare eye disease that gradually affects the center of your vision, making everyday tasks like reading and recognizing faces increasingly difficult over time.

When you look at something directly in front of you, you’re relying on a tiny but incredibly important part of your eye called the macula. This is the area in the center of your retina – the light-sensing tissue at the back of your eye – that allows you to see fine details clearly. Macular telangiectasia, often shortened to MacTel, is a disease that damages this critical area through changes in the small blood vessels that surround it.[1]

The condition gets its name from what happens in the eye. “Telangiectasia” refers to the widening or dilation of tiny blood vessels. In MacTel, the small blood vessels around the very center of the macula, called the fovea, become abnormal. They may swell, leak fluid, or grow in unusual patterns. Over months and years, this causes the delicate structures in the macula to deteriorate, leading to a slow loss of sharp central vision.[4]

Types of Macular Telangiectasia

Doctors have identified different types of macular telangiectasia, though they don’t all affect people in the same way. Type 1 MacTel involves blood vessels that enlarge and develop small bulges called aneurysms. These vessels leak fluid into the macula, causing swelling known as macular edema. Type 1 usually affects only one eye and is believed to be related to a condition called Coats disease, which most often affects young men.[2]

Type 2 MacTel is by far the most common form of the disease. Unlike Type 1, it typically affects both eyes, although each eye may progress at a different rate or be affected more severely than the other. In Type 2, the blood vessels in the macula become dilated and leak, causing the macula to swell and eventually leading to scarring and vision loss. This form is most often diagnosed in people in their 40s and 50s.[5]

There is also a Type 3 MacTel, but it is extremely rare and not well understood by medical professionals. It can lead to blocked blood vessels in the eyes.[5]

How Common Is Macular Telangiectasia?

Macular telangiectasia is considered a relatively rare condition, though experts believe it may be more common than currently recognized. One reason for this is that MacTel can be mistaken for other, more familiar eye diseases such as age-related macular degeneration or diabetic retinopathy. Because of this potential for misdiagnosis, obtaining an accurate diagnosis is important for patients to receive appropriate care and support.[2]

A study conducted in Beaver Dam, Wisconsin, examined eye photographs from nearly 4,800 people between the ages of 43 and 84. Among this group, five individuals were found to have MacTel Type 2, suggesting a prevalence of about 0.1 percent, with an average age of 63 years at the time of identification. Based on global population estimates, experts believe approximately 2 million people worldwide have MacTel.[4][5]

The disease affects men and women in roughly equal numbers and shows no preference based on ethnicity or occupation. It is typically diagnosed in middle-aged adults, most commonly in their 50s or 60s, although the disease has likely been progressing silently for many years or even decades before symptoms become noticeable.[4]

What Causes Macular Telangiectasia?

The exact cause of macular telangiectasia remains a mystery to scientists and doctors. For many years, experts believed MacTel was primarily a problem with blood vessels in the eye. However, recent research has shifted this understanding. Scientists now think that MacTel Type 2 is actually a neurodegenerative disease, meaning it involves the progressive damage and death of nerve cells and their supporting structures in the retina.[4]

The current thinking is that the disease begins with dysfunction in specialized cells called Müller cells. These cells are critical for maintaining the health and structure of the retina. They provide nutrients to photoreceptors, the cells that detect light and allow us to see. They also help maintain the blood-retinal barrier, which protects the retina from harmful substances in the bloodstream. When Müller cells become dysfunctional or die, the photoreceptors and other retinal neurons that depend on them also deteriorate. The changes in blood vessels that are visible in MacTel are believed to be secondary consequences of this underlying nerve cell damage.[4]

One of the main jobs of Müller cells is to produce a protein called ciliary neurotrophic factor, or CNTF. This protein acts as a powerful protector of photoreceptors and supports their normal function. Research in laboratory animals has shown that when Müller cells are depleted, photoreceptors are lost, blood vessels develop telangiectasia, and the blood-retinal barrier breaks down – mimicking what happens in human MacTel.[23]

⚠️ Important
MacTel Type 2 is now understood to be a neurodegenerative disease rather than simply a vascular problem. This shift in understanding has changed how researchers and doctors think about treatment, with a focus on protecting nerve cells rather than just addressing blood vessel changes.

Risk Factors for Developing MacTel

While the root cause of MacTel remains unclear, certain factors appear to increase a person’s risk of developing the condition. Age is one of the most consistent risk factors. The disease most commonly becomes noticeable in people in their 40s through 60s, though it has likely been developing for years before symptoms appear.[4]

There is evidence that genetics may play a role in MacTel Type 2. The condition can run in families, suggesting a possible genetic link. Some genetic markers have been identified in research studies, but scientists have not yet discovered a single specific gene that causes the disease. This makes genetic testing for MacTel complicated and not routinely available.[2]

Other health conditions may also contribute to the development or progression of MacTel. High blood pressure, diabetes, and metabolic syndrome – a cluster of conditions that includes high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels – may affect the health of blood vessels in the eye and the metabolism of the retina. Maintaining good control of blood pressure and blood sugar may help protect eye health in people at risk for MacTel.[5]

Lifestyle choices and environmental factors may also play a part in the disease, though research in this area is ongoing. The disease affects both men and women equally and does not show preference based on race or ethnicity.[4]

Recognizing the Symptoms

In its earliest stages, macular telangiectasia may not cause any noticeable symptoms at all. Many people with early MacTel have no idea anything is wrong with their vision. This is one reason why the disease can progress silently for years before being detected.[5]

As the disease advances, symptoms begin to appear gradually. One of the first things people notice is the development of paracentral scotomas – small blind spots that appear near, but not directly in, the center of vision. These blind spots are most noticeable during activities that require detailed central vision, such as reading. Letters or words may seem to disappear as they fall into these scotomas. Reading speed typically slows as the brain struggles to fill in the missing information.[23]

People with MacTel often describe their vision as blurry or distorted. Straight lines may appear wavy or bent. They may have trouble seeing fine details or small print. As the disease progresses, the scotomas can move from the periphery of central vision to become truly central, affecting the ability to see things directly in front of them. Tasks that require sharp central vision – such as reading, writing, driving, recognizing faces, or doing detailed work – become increasingly difficult.[5]

Many people with MacTel also report trouble seeing in low-light conditions or at night. This can make activities like night driving particularly challenging and anxiety-provoking. Some patients lose confidence in their ability to see vehicles or other hazards that enter their blind spots while driving.[23]

It’s important to understand that MacTel affects central vision but typically does not affect peripheral or side vision. This means that people with MacTel rarely become completely blind. However, the loss of central vision can significantly impact quality of life and the ability to perform everyday activities.[2]

Vision loss from MacTel Type 2 typically progresses slowly over many years – sometimes 10 to 20 years or more. On average, people with MacTel lose about one letter on a standard eye chart each year. While this may sound like a small amount, over time it adds up to significant vision impairment.[23]

⚠️ Important
If you notice a sudden loss of vision or a rapid worsening of symptoms, contact your eye doctor immediately. This could be a sign of complications such as subretinal neovascularization – the growth of abnormal new blood vessels under the retina – which can be treated if caught early.

Can Macular Telangiectasia Be Prevented?

Unfortunately, because the exact cause of macular telangiectasia is not fully understood, there are no proven strategies to prevent the disease from developing in the first place. However, there are steps that may help protect overall eye health and potentially slow the progression of MacTel in people who have been diagnosed.

Maintaining good control of existing health conditions is important. If you have high blood pressure or diabetes, working with your doctor to keep these conditions well-managed may help protect the blood vessels in your eyes. The same applies to keeping cholesterol levels in a healthy range.[5]

Regular eye examinations are crucial, especially for people in middle age or those with a family history of MacTel. Early detection allows for closer monitoring and earlier intervention if complications develop. Because MacTel can be mistaken for other eye conditions, getting an accurate diagnosis from an eye care specialist experienced in retinal diseases is important.

Some research has explored whether nutritional supplements, particularly carotenoids (plant pigments found in colorful fruits and vegetables), might help protect the retina in MacTel. However, studies of carotenoid supplementation have had mixed results and have not shown consistent benefit. There is currently no vitamin or supplement that has been proven to prevent or slow MacTel.[11]

Protecting your eyes from bright sunlight by wearing sunglasses outdoors is a good general practice for eye health, though there is no specific evidence that this prevents MacTel. Similarly, not smoking and maintaining a healthy diet rich in fruits, vegetables, and omega-3 fatty acids supports overall health and may benefit the eyes.

Understanding What Happens in the Eye

To understand how MacTel affects vision, it helps to know a bit about how the eye normally works. The retina is the light-sensitive layer at the back of the eye that converts light into electrical signals sent to the brain. The macula is a small area in the center of the retina responsible for sharp, detailed central vision. At the very center of the macula is the fovea, a tiny pit packed densely with photoreceptors called cone cells, which allow us to see fine details and colors.[1]

In MacTel Type 2, several changes occur in and around the macula. The disease begins with dysfunction of Müller cells, which are specialized supporting cells that run through the thickness of the retina. These cells normally provide structural support, deliver nutrients to photoreceptors, remove waste products, and maintain the proper chemical environment for vision to occur. When Müller cells become dysfunctional, they can no longer perform these vital jobs effectively.[4]

As Müller cells deteriorate, photoreceptors in the macula begin to die off. This loss of photoreceptors creates small cavities or empty spaces in the retina that can be seen on imaging tests. The outer layers of the retina, where photoreceptors are located, become disorganized and thin. A specific layer called the ellipsoid zone, which is part of the photoreceptors, gradually shrinks in area – a key marker of disease progression.[4]

The blood vessels near the fovea also undergo changes. They become dilated (widened) and twisted, sometimes forming right-angled branches. These abnormal vessels are more prone to leaking fluid and blood components into the surrounding retina. When this happens, the retina swells, a condition called macular edema. Over time, pigment cells from deeper layers of the retina may migrate into areas where they don’t normally belong, creating dark spots visible during examination.[8]

In some people with MacTel, small crystal-like deposits form in the retina. The exact nature and significance of these crystals is not fully understood, but they are thought to represent accumulated waste products that the dysfunctional retina cannot properly clear away.[8]

As the disease progresses, one of the most serious complications that can develop is subretinal neovascularization, often shortened to SNV. This means that new, abnormal blood vessels grow beneath the retina. These vessels are fragile and leak easily, causing rapid vision loss through bleeding, severe swelling, and eventually scarring. SNV is responsible for much of the severe vision loss that occurs in advanced MacTel.[4]

Another change that occurs is the development of areas of retinal pigment epithelium hyperplasia. The retinal pigment epithelium, or RPE, is a layer of cells beneath the retina that normally supports photoreceptor function. In MacTel, these cells can multiply and clump together, creating dark pigmented areas that further interfere with vision.[4]

All of these changes – the loss of Müller cells and photoreceptors, the vascular abnormalities, the fluid leakage, and the development of scar tissue – work together to gradually destroy the fine structure of the macula that is necessary for clear central vision. Understanding this process has helped researchers develop new approaches to treatment.

Ongoing Clinical Trials on Macular telangiectasia

  • Study Comparing Aflibercept and Placebo for Patients with Macular Telangiectasia Type 1

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

References

https://www.mdfoundation.com.au/about-macular-disease/other-macular-conditions/macular-telangiectasia/

https://www.macularsociety.org/macular-disease/macular-conditions/mac-tel/

https://preventblindness.org/mactel/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9553319/

https://www.webmd.com/eye-health/macular-telangiectasia-overview

https://www.mdfoundation.com.au/about-macular-disease/other-macular-conditions/macular-telangiectasia/?textonly=true

https://www.retinaassociatesofgreaterphiladelphia.com/disorders-treated/macular-telangiectasia/

https://www.illinoisretina.com/blog/macular-telangiectasia-april-2017

https://www.ophthalmologytimes.com/view/a-new-era-for-mactel-clinicians-react-to-fda-approval-of-revakinagene-taroretcel-lwey

https://www.houstonmethodist.org/leading-medicine-blog/articles/2025/may/fda-approves-first-treatment-for-macular-telangiectasia-type-2-with-houston-methodist-among-top/

https://pmc.ncbi.nlm.nih.gov/articles/PMC6514016/

https://www.fightingblindness.org/news/neurotech-s-encapsulated-cell-technology-receives-fda-approval-for-treatment-of-mactel-1960

https://www.healio.com/news/ophthalmology/20250107/management-of-macular-telangiectasia-type-2-may-be-near

https://preventblindness.org/mactel/

https://www.mdfoundation.com.au/about-macular-disease/other-macular-conditions/macular-telangiectasia/

https://med.emory.edu/departments/ophthalmology/about/news-eec/2022/3-mactel.html

https://www.uncoveringmactel.com/living-with-mactel/

https://preventblindness.org/mactel/

https://www.mdfoundation.com.au/about-macular-disease/other-macular-conditions/macular-telangiectasia/

https://www.webmd.com/eye-health/what-is-macular-telangiectasia-type-2

https://www.newretinalphysician.com/issues/2022/julyaugust/so-you-have-diagnosed-mactel-now-what/

https://www.macularsociety.org/macular-disease/macular-conditions/mac-tel/

https://www.ophthalmologytimes.com/view/a-roadmap-to-preserving-the-prime-years-of-patients-diagnosed-with-mactel

https://specialty.vision/article/understanding-macular-telangiectasia-type-2-and-its-impact-on-vision/

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

https://www.roche.com/stories/terminology-in-diagnostics

FAQ

Will I go completely blind from macular telangiectasia?

MacTel does not cause total blindness. It affects central vision but typically does not damage peripheral or side vision. While you may lose the ability to see fine details directly in front of you, you will retain your side vision, which helps with mobility and general orientation.

How is MacTel different from age-related macular degeneration?

While both conditions affect the macula and can cause similar symptoms, they are different diseases. MacTel typically appears earlier (in the 40s to 60s) compared to age-related macular degeneration, and it involves different underlying mechanisms. MacTel is now understood to be primarily a neurodegenerative disease affecting Müller cells, while macular degeneration involves different processes. However, MacTel is often misdiagnosed as macular degeneration, which is why getting an accurate diagnosis from a retinal specialist is important.

Is there a genetic test for macular telangiectasia?

Currently, there is no single genetic test that can diagnose MacTel. While the condition can run in families and some genetic markers have been identified in research studies, scientists have not yet found a specific gene or set of genes responsible for the disease. Diagnosis is made through clinical examination and imaging tests rather than genetic testing.

How quickly does MacTel progress?

MacTel Type 2 typically progresses slowly over many years – often 10 to 20 years or more. On average, people lose about one letter of visual acuity on an eye chart each year. However, progression rates can vary significantly between individuals and between the two eyes in the same person. If complications like subretinal neovascularization develop, vision loss can occur more rapidly.

What is the MacTel Project?

The MacTel Project is a large research study and registry of patients with MacTel sponsored by the Lowy Medical Research Institute. More than 60 centers around the world participate in this natural history study, which tracks how the disease progresses over time and helps advance research into potential treatments. Patients with MacTel can enroll in the registry to help advance research and may have opportunities to participate in clinical trials.

🎯 Key Takeaways

  • Macular telangiectasia is a rare eye disease that gradually damages central vision but does not cause complete blindness, as peripheral vision is preserved.
  • MacTel Type 2 is now understood to be a neurodegenerative disease affecting Müller cells in the retina, rather than simply a blood vessel problem.
  • The disease typically becomes noticeable in people in their 40s to 60s, though it has likely been progressing silently for years or decades.
  • MacTel is often misdiagnosed as age-related macular degeneration or diabetic retinopathy, making accurate diagnosis by a retinal specialist important.
  • Early symptoms include small blind spots near the center of vision, slowed reading speed, blurred or distorted vision, and difficulty seeing in low light.
  • In March 2025, the FDA approved the first treatment for MacTel – an implantable device that continuously delivers a protective protein to slow disease progression.
  • If subretinal neovascularization develops as a complication, anti-VEGF injections can help preserve vision when started early.
  • The MacTel Project connects patients worldwide with research opportunities and clinical trials aimed at better understanding and treating this condition.

Connected medications: